NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03926936 2024-05-28
FUCHSia
University Hospital, Gasthuisberg
Phase 2 Completed
NCT00334295 2012-07-31
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
AstraZeneca
Phase 2 Completed